The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...
GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...
Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
GlaxoSmithKline ( (GSK) ) has provided an update.Don't Miss Our New Year's Offers:Discover the latest stocks recommended by top Wall Street ...
The FTSE 100 is expected to open flat on Friday, having closed up 1.1% on Thursday at 8,260.09.